Results 121 to 130 of about 119,907 (304)

Suspected bradycardia due to interactions between HIV protease inhibitors and lidocaine: a case report. [PDF]

J Dent Anesth Pain Med, 2021
Hamaya E, Kamekura N, Fujisawa T.
europepmc   +1 more source

Fullerene-based inhibitors of HIV-1 protease

Journal of Peptide Science, 2015
A series of Fmoc-Phe(4-aza-C60)-OH of fullerene amino acid derived peptides have been prepared by solid phase peptide synthesis, in which the terminal amino acid, Phe(4-aza-C60)-OH, is derived from the dipolar addition to C60 of the Fmoc-Nα-protected azido amino acids derived from phenylalanine: Fmoc-Phe(4-aza-C60)-Lys3-OH (1), Fmoc-Phe(4-aza-C60)-Pro ...
Serdar Durdagi, Serdar Durdagi, Suha Salih Ersoz, T. Amanda Strom, Claudiu T. Supuran, Andrew R. Barron, Andrew R. Barron, Ramin Ekhteiari Salmas   +7 more
openaire   +6 more sources

Development of a physiologically‐based pharmacokinetic model for Ritonavir characterizing exposure and drug interaction potential at both acute and steady‐state conditions

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 523-539, March 2025.
Abstract Ritonavir (RTV) is a potent CYP3A inhibitor that is widely used as a pharmacokinetic (PK) enhancer to increase exposure to select protease inhibitors. However, as a strong and complex perpetrator of CYP3A interactions, RTV can also enhance the exposure of other co‐administered CYP3A substrates, potentially causing toxicity.
Lien Thi Ngo, Woojin Jung, Tham Thi Bui, Hwi‐yeol Yun, Jung‐woo Chae, Jeremiah D. Momper   +5 more
wiley   +1 more source

HIV Protease Inhibitors and Insulin Sensitivity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. [PDF]

Front Pharmacol, 2021
Kajogoo VD, Gorret Atim M, Amare D, Geleta M, Muchie Y, Tesfahunei HA, Olomi W, Acam J, Manyazewal T.   +8 more
europepmc   +1 more source

Era of direct acting anti-viral agents for the treatment of hepatitis C. [PDF]

, 2018
Hepatitis C infection is universal and the most common indication of liver transplantation in the United States. The period of less effective interferon therapy with intolerable side effects has gone.
Ahmed, Monjur
core   +1 more source

Nature Inspired Delivery Vehicles for CRISPR‐Based Genome Editing

Small, EarlyView.
The review highlights nature‐inspired nanocarriers for CRISPR delivery, emphasizing viral vectors, extracellular vesicles, liposomes, and lipid nanoparticles. It discusses their roles in improving specificity, minimizing immunogenicity, and overcoming barriers in genome editing. Recent advancements, challenges, and therapeutic applications are explored,
Elizabeth Maria Clarissa, Mamata Karmacharya, Hyunmin Choi, Sumit Kumar, Yoon‐Kyoung Cho   +4 more
wiley   +1 more source

Endourological management of a rare radiopaque ritonavir-composed urinary calculus

Urology Case Reports, 2021
Protease inhibitors are a source of nephrolithiasis in HIV + patients, and these stones are described as not detected by CT. While urinary stones are commonly associated with certain protease inhibitors, stones composed of ritonavir are rare.
Folawiyo Laditi, Amir Ishaq Khan, Eric M. Ghiraldi, Tashzna Jones, Ankur Choksi, Dinesh Singh   +5 more
doaj  

THE TRANSPORT AND MODULATION OF HIV PROTEASE INHIBITORS INTO THE RAT CENTRAL NERVOUS SYSTEM AND MILK [PDF]

, 2004
The objective of this dissertation is to study the mechanism by which HIV protease inhibitors enter into the central nervous system (CNS) and breast milk of rats, and what effects MDR modulators have on the distribution and metabolism of HIV protease ...
Edwards, Jeffrey Earl
core   +1 more source

Design of HIV-1-PR inhibitors which do not create resistance: blocking the folding of single monomers

, 2005
One of the main problems of drug design is that of optimizing the drug--target interaction. In the case in which the target is a viral protein displaying a high mutation rate, a second problem arises, namely the eventual development of resistance.
Abkevich, Bahar, Baldwin, Berendsen, Borg, Broglia, Broglia, Broglia, Broglia, Cecconi, Cheng, Davide Provasi, Fabio Simona, Gō, Grant, Guido Tiana, Holm, Holzman, Ishima, Kaya, Kikuchi, Lesk, Levy, Levy, Levy, Li, Ludovico Sutto, Mirny, Panchenko, Pearson, Ptitsyn, Rey, Ricardo A. Broglia, Sander, Shafer, Szeltner, Tiana, Tiana, Tiana, Tiana, Tiana, Todd, Tomasselli, Wallqvist, Xie, Zhang   +45 more
core   +2 more sources

Toward the design of potent dual inhibitors of HIV-1 and HIV-2 proteases [PDF]

, 1993
Boyang Zhao
openalex   +1 more source